Takeda submits second diabetes combo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Takeda submits its oral pioglitazone/glimepiride combination to FDA for use in type 2 diabetes, the firm announces June 30. Pioglitazone is the active ingredient of the Japanese firm's Actos. Takeda has a second combo product, Actoplus Met (pioglitazone/metformin), pending at FDA with an estimated user fee date of Aug. 28...